A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients With Relapsed or Refractory Advanced Solid Tumors
Latest Information Update: 11 Apr 2024
At a glance
- Drugs IMGS-001 (Primary)
- Indications Adenocarcinoma; Bladder cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors IMMUNOGENESIS
- 28 Sep 2023 According to an IMMUNOGENESIS media release, first patient has been dosed at The University of Texas MD Anderson Cancer Center in Houston, Texas.
- 23 Aug 2023 Status changed from planning to recruiting.
- 27 Jun 2023 According to an IMMUNOGENESIS media release, Cancer Focus Fund plans to invest $4.5 million to support this trial which is being conducted at the MD Anderson. Dr. David S. Hong, Professor of Investigational Cancer Therapeutics at MD Anderson, will serve as Principal Investigator of the trial.